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Abstract
Introduction
Murine studies have shown that apolipoprotein E modulates pulmonary function during
development, aging, and allergen-induced airway disease. It is not known whether the poly-
morphic human APOE gene influences pulmonary function.
Objectives
We assessed whether an association exists between the polymorphic human APOE ε2, ε3,
and ε4 alleles and pulmonary function among participants in the Long Life Family Study.
Methods
Data from 4,468 Caucasian subjects who had genotyping performed for the APOE ε2, ε3,
and ε4 alleles were analyzed, with and without stratification by sex. Statistical models were
fitted considering the effects of the ε2 allele, defined as ε2/2 or ε2/3 genotypes, and the ε4
allele, defined as ε3/4 or ε4/4 genotypes, which were compared to the ε3/3 genotype.
Results
The mean FEV1/FVC ratio (the forced expiratory volume in one second divided by the forced
vital capacity) was lower among women with the ε4 allele as compared to women with the
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ε3/3 genotype or the ε2 allele. Carriage of the APOE ε4 allele was associated with FEV1/
FVC, which implied lower values. Further analysis showed that the association primarily
reflected women without lung disease who were older than 70 years. The association was
not mediated by lipid levels, smoking status, body mass index, or cardiovascular disease.
Conclusions
This study for the first time identifies that the APOE gene is associated with modified lung
physiology in women. This suggests that a link may exist between the APOE ε4 allele,
female sex, and a reduction in the FEV1/FVC ratio in older individuals.
Introduction
Apolipoprotein E (APOE) plays an essential role in normal lipid homeostasis by removing tri-
glyceride- and cholesterol-containing lipoprotein particles from plasma by binding to cellular
receptors of the LDL receptor (LDLR) family[1–3]. Consistent with this, individuals with
familial APOE deficiency have severely disrupted lipid catabolism with type III hyperlipopro-
teinemia and premature cardiovascular disease[4]. In addition to lipid transport, APOE also
has important anti-oxidant and anti-inflammatory properties[5–7].
The APOE protein is primarily synthesized by the liver and circulates in plasma[2, 3].
APOE is also expressed by macrophages, alveolar epithelial cells and pulmonary artery smooth
muscle cells in the lung, where it may regulate respiratory health and disease[7–12]. For exam-
ple, a role for APOE in normal lung development has been suggested as male Apoe-deficient
mice have increased airway resistance in early adulthood and more rapid loss of lung recoil
with age[13, 14]. This suggested that altered lipid metabolism in the absence of APOE may
increase inflammation and oxidative stress with resultant abnormal lung mechanics. APOE
may also modulate normal surfactant phospholipid synthesis by type II airway epithelial cells.
Apoe-deficient mice have increased alveolar levels of the major surfactant lipid, disaturated
phosphatidylcholine, which occurs as a consequence of elevated serum levels of triglycerides
and very low-density lipoproteins (VLDL)[15]. Studies in murine models have shown that
feeding Apoe-deficient mice a high-fat Western diet causes cholesterol accumulation in the
lung with resultant pathogenic changes resembling emphysema, pulmonary fibrosis, pulmo-
nary hypertension, and sarcoidosis[7, 16–21]. APOE also has been shown to have protective
roles in murine models of asthma, acute lung injury (ALI), emphysema, and pulmonary hyper-
tension[7, 10, 12, 22–25]. For example, APOE can directly bind and neutralize lipopolysaccha-
ride from the cell walls of gram-negative bacteria, which may be a protective mechanism in
ALI[26–29]. APOE can also bind mycobacterial lipid antigens, which are then internalized by
antigen-presenting cells, which promotes adaptive immune responses to Mycobacterium tuber-
culosis[30].
It is not known whether the polymorphic human APOE gene influences pulmonary func-
tion. Here, we hypothesized that the common polymorphic APOE alleles, ε2, ε3 and ε4, might
be associated with modified lung function among 4,554 participants of the Long Life Family
Study (LLFS), which is a family-based cohort study that has the goal of identifying factors
related to human longevity. We focused on spirometric measures of lung function, including
the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC), and the
FEV1/FVC ratio (FEV1 divided by the FVC). These are standardized, universal measurements
of air flow in and out of lungs that are routinely used, in both clinical care and research, to
The APOE ε4 allele is associated with a reduction of FEV1/FVC in women
PLOS ONE | https://doi.org/10.1371/journal.pone.0206873 November 9, 2018 2 / 14
Request, can be found at the following website:
https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?login=
&page=login. The requirement that investigators
submit an application to dbGAP for data access is
to ensure that patient confidentiality is protected.
Funding: The Long Life Family Study is funded by
U01AG023749, U01AG023744, U01AG049508 and
U01AG023712 from the National Institute on
Aging, NIH, USA. This work was supported by the
National Institute on Aging (grant numbers U01
AG023712, P01 AG043352, R01 AG047310) and
the Division of Intramural Research, NHLBI
(1ZIAHL006053-08), NIH, USA. The funding
source did not participate in the writing of the
manuscript or the decision to submit the
manuscript for publication. The content is solely
the responsibility of the authors and does not
necessarily represent the official views of the
National Institutes of Health.
Competing interests: The authors have declared
that no competing interests exist.
quantify and monitor obstructive lung diseases, such as asthma and chronic obstructive pul-
monary disease (COPD), as well as restrictive lung disease, such as pulmonary fibrosis.
Methods
The Long-life family study
Baseline information from 4,954 U.S. and Danish LLFS participants was collected at four field
centers using similar questionnaires and in-home physical examinations between 2006 and
2009 on families showing exceptional familial longevity ranked on the basis of a Family Lon-
gevity Selection Score, which is a summary-measure of the survival experience of the oldest liv-
ing generation of siblings relative to what would be expected based on the life tables of a
normal population. Disease information was assessed both retrospectively, from self-reports at
baseline, and prospectively through 2015. Other eligibility criteria, as well as the design of the
LLFS study have previously been described [31–35]. In brief, the U.S. families eligible for the
LLFS study must have at least two living siblings aged 80+ years, two living offspring, and a liv-
ing spouse of either siblings or offspring. Eligible families were enrolled in LLFS if at least
three living members (a proband, at least one sibling, and one of their offspring) were willing
to participate. In Denmark, individuals who would be aged 90+ years according the Danish
National Register of Person were identified and contacted to further assess the family’s eligibil-
ity using criteria parallel to those used in the U.S.[34]. Thus, the LLFS includes long-living
individuals (probands and siblings), their offspring, and spouses of probands and offspring.
Local institutional review boards of all participating centers approved the LLFS (University
of Southern Denmark S-VF-2003227; Boston University H-25140; Columbia University
AAAP4119; University of Pittsburgh IRB0509062 and PRO14050142) and all participants pro-
vided informed consent[36].
Sample collection and processing
Baseline blood samples were collected from all LLFS participants and processed within 48 to
72 hours to isolate serum, plasma, DNA and cryopreserved lymphocytes. DNA was isolated
from white blood cells using the automated Autopure DNA extraction method (Qiagen Inc.,
Gaithersburg, MD). For the 4% of participants from whom blood could not be obtained, DNA
was isolated from buccal samples using Oragene kits (DNA Genotek, Ottawa, ON, Canada).
The data presented in this manuscript utilized DNA from both sources. Lipid measurements
were made from serum.
APOE genotyping
Genotyping of the APOE ε2, ε3, and ε4 alleles for LLFS study participants was performed at
the Biomedical Genomics Center at the University of Minnesota[37]. APOE genotyping was
based on SNPs rs7412 and rs429358 using the Taqman genotyping platform and concordance
among genotypes for both SNPs was 100% based on blinded duplicates. The frequencies of the
APOE genotypes in a sample of 4,554 LLFS participants were ε2/ε2 (n = 32, 0.7%); ε2/ε3
(n = 683, 15.0%); ε2/ε4 (n = 86, 1.9%); ε3/ε3 (n = 2959, 65.0%); ε3/ε4 (n = 746, 16.4%); and
ε4/ε4 (n = 48, 1.0%). The APOE genotypes were in Hardy-Weinberg equilibrium (p = 0.754),
thereby implying that the observed genotype distribution did not deviate from the expected
distribution in this population. Given the small number of carriers of the three uncommon
genotypes, ε2/ε2, ε2/ε4, and ε4/ε4 (3.6% of the LLFS participants), we selected three groups
for analysis. The ε2 allele was defined as ε2/ε2 or ε2/ε3 genotypes, the ε4 allele was defined as
ε3/ε4 or ε4/ε4 genotypes, and the ε3/ε3 genotype was designated as the reference group for
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the association analyses using regression models (see Analysis section). Statistical models were
fitted considering the effect of the ε2 and ε4 alleles as compared to the common ε3/ε3 refer-
ence genotype.
We prospectively determined that participants with the ε2/ε4 genotype would not be
included in the models to avoid biasing the effects of the ε4 allele on pulmonary function by
the ε2 allele. After exclusion of carriers of the APOE ε2/ε4 genotype, 4,468 Caucasian LLFS
participants were analyzed. They included long-living (LL) individuals (N = 1,302), their off-
spring (N = 2,259), spouses of LL individuals (N = 158), and spouses of offspring (N = 749).
Lung function outcomes
Quantitative markers of lung function, FEV1, FVC, and FEV1/FVC (%), were considered as
outcomes. Lung function was measured with a portable spirometer (EasyOne, ndd Medical
Technologies, Andover, MA) using American Thoracic Society guidelines[38].
Analysis
In the initial analyses, mean values (age, BMI, FEV1, FVC, FEV1/FVC) and proportions (sex,
smoking) over three groups of individuals carrying the ε2 allele (ε2/ε2 or ε2/ε3 genotypes),
the ε3/ε3 genotype, and the ε4 allele (ε4/ε4 or ε3/ε4 genotypes) were compared using one-
way ANOVA with 2 degrees of freedom that does not require correction for multiple compari-
sons. Associations of the selected APOE genotypes with outcomes were characterized by a
two-level mixed effects linear regression model (lme4 package in R) with a random effect to
adjust for the LLFS familial structure. Measurement of FEV1, FVC and FEV1/FVC were used
in their natural scale because no noticeable skewness of their frequency distributions was
detected. These statistical models were fitted considering the effect of the ε2 and ε4 alleles as
compared to the common ε3/ε3 reference genotype.
Analyses of pooled samples and sex-stratified samples were performed. A test of multiplica-
tive interactions was conducted to quantify differences in the effects between men and
women. All statistical tests were adjusted for age, field center, family groups (i.e., probands,
their offspring, and spouses) and sex, when applicable.
We investigated whether height, smoking, lipids, and body mass index (BMI) modulated
associations of the APOE genotypes with FEV1, FVC and FEV1/FVC using models adjusted
for each of these factors. BMI was calculated as weight (kg)/height (m)2. Standing height was
measured using a Handi-stat set square (Perspective Enterprises, Portage, MI) to the nearest
0.1 cm. Weight was measured using an electronic digital scale (SECA 841, Hanover, MD) to
the nearest 0.1 kg. Smoking was defined as current smokers. Total cholesterol, LDL- choles-
terol (LDL-C), HDL-cholesterol (HDL-C), and triglycerides were measured in serum on a
Roche/Modular P Chemistry Analyzer (Roche Diagnostics Corporation) using samples
obtained after a 6-hour fast, which could occur during any time of the day. Total cholesterol
was measured using a cholesterol oxidase enzymatic method and triglycerides were measured
using a glycerol blanking enzymatic method (Roche Diagnostics, Indianapolis, IN). LDL-C
was calculated using the Friedewald equation[39].
All analyses were conducted in R.
Results
The 4,468 LLFS participants had a mean age of 70.06 ± 0.23 years and included 2,041 (44.82%)
men. 636 subjects reported having lung disease, while 3,832 subjects were without lung disease.
The frequencies of the selected three common APOE genotypes among men and women com-
bined, as well as separately are shown in Table 1. The ε3/3 genotype was carried by 66.2% of
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LLFS participants (men and women combined), followed by ε4 and ε2 being carried by 17.8%
and 16.0%, respectively. Carriers of the ε4 allele were the youngest and carriers of the ε2 allele
were the oldest. The proportion of men was smallest among the ε3/ε3 carriers and largest
among the ε2 carriers. Mean values of FEV1 and FVC were larger among ε4 carriers as
Table 1. Baseline demographic characteristics and outcomes used in the analyses of the genotyped LLFS participants for men and women combined and separately.
Factor APOE p-value (ANOVA)
ε2 = ε2/ε2 or ε2/ε3 ε3/ε3 ε4 = ε4/ε4 or ε3/ε4
Men and Women
N (%†) 715 (16.00) 2959 (66.23) 794 (17.77)
Age, mean (SE), years 71.23 (0.63) 70.58 (0.29) 67.23 (0.49) <0.001�
Sex, Male, N (%†) 345 (48.25) 1292 (43.66) 369 (46.47) .053
Smoking, N (%†) 302 (42.30) 1238 (41.95) 358 (45.32) .233
BMI, mean (SE), kg/m2 27.40 (10.01) 27.14 (9.43) 26.90 (9.75) .151
CVD, N (%†) 189 (26.43) 789 (26.66) 185 (23.30) .153
FEV1, mean (SE), [mL] 2398 (33) 2400 (16) 2571 (31) <0.001
�
FVC, mean (SE), [mL] 3121 (41) 3129 (20) 3366 (38) <0.001�
FEV1/FVC, mean (SE) [%] 76.40 (0.28) 76.29 (0.14) 75.82 (0.27) .261
Men
N (%†) 345 (17.20) 1292 (64.41) 369 (18.39)
Age, mean (SE), years 71.54 (0.88) 71.08 (0.43) 67.91 (0.71) <0.001�
Smoking, N (%†) 166 (48.26) 639 (49.57) 185 (50.41) .845
BMI, mean (SE), kg/m2 27.83 (8.33) 27.60 (7.98) 27.21 (7.92) .124
CVD, N (%†) 100 (28.99) 406 (31.42) 106 (28.73) .487
FEV1, mean (SE), [mL] 2806 (49) 2841 (25) 3040 (46) <0.001
�
FVC, mean (SE), [mL] 3664 (58) 3735 (29) 3989 (53) <0.001�
FEV1/FVC, mean (SE) [%] 76.00 (0.44) 75.46 (0.23) 75.67 (0.39) .553
Women
N (%†) 370 (15.03) 1667 (67.71) 425 (17.26)
Age, mean (SE), years 70.94 (0.90) 70.18 (0.40) 66.64 (0.68) <0.001�
Smoking, N (%†) 136 (36.76) 599 (36.04) 173 (40.90) .181
BMI, mean (SE), kg/m2 27.00 (11.31) 26.79 (10.38) 26.63 (11.10) .651
CVD, N (%†) 89 (24.05) 383 (22.98) 79 (18.59) .108
FEV1, mean (SE), [mL] 2018 (35) 2055 (17) 2169 (31) .003
�
FVC, mean (SE), [mL] 2615 (43) 2655 (20) 2834 (36) <0.001�
FEV1/FVC, mean (SE) [%] 76.76 (0.36) 76.95 (0.17) 75.95 (0.38) .044
�
� denotes significant result (p-value < 0.05).
† Percentage is within the considered group of the genotyped sample.
N denotes sample size.
Age is accessed at baseline.
Smoking status was defined as a cumulative smoking history of more than 100 cigarettes.
FEV1 denotes forced expiratory volume in 1 second.
FVC denotes forced vital capacity.
FEV1/FVC is the ratio (%) of FEV1 to FVC.
CVD denotes prevalence of cardiovascular diseases, which included coronary heart disease, heart failure, and stroke.
SE denotes standard error.
Baseline demographic characteristics and phenotypes for lung disease cases and controls without lung disease are given in Table 2.
P-values for the comparison of mean values (age, BMI, FEV1, FVC, FEV1/FVC) and proportions (sex, smoking) amongst three groups of individuals carrying the ε2
allele (ε2/ε2 or ε2/ε3 genotypes), the ε3/ε3 genotype, and the ε4 allele (ε4/ε4 or ε3/ε4 genotypes) were assessed by one-way ANOVA with 2 degrees of freedom.
https://doi.org/10.1371/journal.pone.0206873.t001
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compared to carriers of the ε3/ε3 genotype and ε2 allele when men and women were com-
bined, as well as when stratified by sex. In contrast, the FEV1/FVC ratio was significantly lower
among ε4 female carriers, whereas there was no significant difference in the FEV1/FVC ratio
between APOE allele groups among men and women combined or among men.
Next, we assessed whether an association existed between spirometric values and APOE
alleles in the LLFS participants. Table 2 shows that the ε4 allele is significantly associated with
a 0.70% reduction in FEV1/FVC in the sample of men and women combined (p = 0.0214),
thereby implying that the ε4 allele carriers have smaller FEV1/FVC values. Sex-stratified analy-
sis showed that this effect is mostly attributed to women with a 1.24% reduction in the FEV1/
FVC ratio (p = 0.0014). We also verified that the association with reduced FEV1/FVC in the
sample of men and women combined did not reflect a potential bias related to population
admixture (S1 Table). Further analyses showed that height, smoking, BMI (S2 Table), and lip-
ids (S3 Table) did not mediate the associations of the APOE alleles with FEV1, FVC and FEV1/
FVC. There were no significant interactions between the ε4 allele and BMI or smoking (S4
Table). There were also no significant interactions between the ε4 allele and lipids, except for
HDL-C in men, in relationship to the FEV1/FVC ratio (S5 Table). Furthermore, the ε4 allele
was significantly associated with FEV1/FVC in women with or without cardiovascular disease
(S6 Table).
We next assessed whether this association persisted when we analyzed the large sub-group
of 3,832 control subjects without lung disease (Table 3). This analysis showed a significant
association between the ε4 allele and a 0.72% reduction in FEV1/FVC in the samples of men
and women combined (p = 0.0164), as well as a 1.04% reduction in FEV1/FVC in women
alone (p = 0.0078). We also assessed whether the association between the ε4 allele and FEV1/
FVC in women was specifically related to aging (Table 4). This analysis showed that the associ-
ation between the ε4 allele and FEV1/FVC was significant in long-living women (age
90.8 ± 6.9 years, mean ± standard deviation), but not in the spouses or children of long-living
individuals, or in the spouses of offspring of long-living individuals. Similarly, the association
between the ε4 allele and the FEV1/FVC was significant in LLFS women subjects� 70 years,
but not in LLFS women subjects < 70 years.
Lastly, an analysis of interactions showed that sex modified the effect of the ε4 allele on
FEV1, FVC, and FEV1/FVC in the LLFS participants (Table 5). The interaction between the ε4
allele and sex gained nominal significance (p = 0.045) for FEV1/FVC, while there was a trend
Table 2. Associations of the APOE ε2 and ε4 alleles with FEV1, FVC, and FEV1/FVC of the genotyped LLFS participants for men and women combined and
separately.
Trait Effect
allele
Men & Women Men Women
Beta SE P-value Beta SE P-value Beta SE P-value
FEV1 ε2 -11.24 22.40 .616 9.42 37.63 .802 -34.02 24.75 .169
ε4 1.98 21.70 .927 39.50 37.97 .298 -12.34 23.46 .599
FVC ε2 -34.41 23.09 .211 -44.68 46.19 .333 -34.37 30.95 .267
ε4 23.09 26.08 .376 58.15 45.10 .197 19.93 29.19 .495
FEV1/FVC ε2 0.12 0.32 .709 0.53 0.50 .288 -0.21 0.40 .595
ε4 -0.70 0.30 .021� -0.18 0.47 .703 -1.24 0.39 .001�
The ε3/ε3 genotype was considered as the reference.
SE denotes standard error.
Beta denotes the effect size.
� denotes significant result (p-value < 0.05).
https://doi.org/10.1371/journal.pone.0206873.t002
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for FEV1 (p = 0.060). These results suggest a sexual dimorphism in the associations between
the APOE ε4 allele and FEV1 and FEV1/FVC.
Discussion
The human APOE gene is polymorphic and encodes three distinct protein isoforms, APOE2,
APOE3, and APOE4, which differ by single amino acid substitutions at amino acids 112 and
158[1, 3]. APOE3 is the most common isoform and contains a cysteine at position 112 and an
arginine at position 158, whereas APOE2 contains two cysteines and APOE4 has two arginines
[1]. Although these polymorphisms do not involve the receptor- or lipid-binding domains of
APOE, they significantly alter its structural and functional properties. APOE2 has markedly
Table 3. Associations of the APOE ε2 and ε4 alleles with FEV1, FVC and FEV1/FVC in the sub-group of 3,832 genotyped LLFS participants without lung disease.
Trait Effect
allele
Men & Women Men Women
Beta SE P-value Beta SE P-value Beta SE P-value
FEV1 ε2 -5.44 22.92 .812 12.01 37.73 .750 -23.90 26.13 .360
ε4 10.21 22.15 .645 44.26 38.25 .247 0.11 24.45 .996
FVC ε2 -29.89 29.36 .309 -48.00 48.70 .324 -21.31 33.67 .527
ε4 33.57 27.47 .222 70.34 46.89 .134 31.26 31.42 .320
FEV1/FVC ε2 0.16 0.32 .605 0.45 0.48 .349 -0.03 0.42 .936
ε4 -0.72 0.30 .016� -0.46 0.46 .312 -1.04 0.39 .008�
The models were fitted with adjustments by age, sex, family groups, and field center.
Controls subjects without lung disease are defined in the Methods section.
The ε3/ε3 genotype was considered as the reference.
� denotes significant result (p-value < 0.05).
https://doi.org/10.1371/journal.pone.0206873.t003
Table 4. Associations of the APOE ε2 and ε4 alleles with FEV1/FVC in different age groups of LLFS participants.
Trait Effect
allele
Men & Women Men Women
N Beta SE P-value N Beta SE P-value N Beta SE P-value
FEV1/FVC
LL individuals
ε2 968 0.41 0.73 .575 468 0.34 1.04 .745 500 0.48 1.02 .639
ε4 907 -1.47 0.87 .098 437 0.05 1.21 .967 470 -2.98 1.23 .027�
FEV1/FVC
LL spouses
ε2 112 1.25 1.76 .513 23 2.75 3.11 .388 89 1.76 2.11 .466
ε4 121 -3.08 1.63 .200 26 -0.30 2.62 .909 95 -4.05 2.01 .294
FEV1/FVC
LL offspring
ε2 1696 -0.27 0.36 .450 713 0.31 0.60 .612 983 -0.59 0.42 .169
ε4 1739 -0.36 0.34 .286 731 -0.27 0.54 .623 1008 -0.55 0.43 .206
FEV1/FVC
Offspring spouses
ε2 533 0.67 0.85 .436 277 1.40 1.27 .282 256 -0.43 1.07 .694
ε4 630 -0.55 0.62 .378 315 -0.37 1.01 .714 315 -0.87 0.71 .225
FEV1/FVC
age < 70
ε2 1914 -0.21 0.35 .554 826 0.43 0.57 .450 1088 -0.58 0.42 .169
ε4 2051 -0.30 0.31 .340 886 -0.24 0.50 .629 1165 -0.39 0.39 .318
FEV1/FVC
age� 70
ε2 1395 0.59 0.58 .307 655 0.89 0.86 .305 740 0.34 0.77 .657
ε4 1346 -1.76 0.63 .006� 623 -0.06 0.95 .947 723 -3.19 0.84 <0.001�
LL indicates long-living individuals. Mean age and standard deviation (SD) for LL individuals were: 90.4 ± 6.4 years (men and women combined), 89.8 ± 5.7 years
(men) and 90.8 ± 6.9 years (women). Mean age and SD for spouses of LL individuals were: 83.1 ± 7.0 years (men and women combined), 85.3 ± 5.5 years (men) and
82.5 ± 7.3 years (women). Mean age and SD for offspring of LL individuals were: 60.5 ± 8.2 years (men and women combined), 60.6 ± 8.2 years (men) and 60.5 ± 8.2
years (women). Mean age and SD for spouses of offspring were: 60.9 ± 8.6 years (men and women combined), 63.1 ± 7.9 years (men) and 58.4 ± 8.7 years (women).
LLFS participants were also divided into subjects < or� 70 years of age.
� denotes significant result (p-value < 0.05).
https://doi.org/10.1371/journal.pone.0206873.t004
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impaired LDLR binding capabilities, which is less than 2% of APOE3 and APOE4[2]. The
APOE4 isoform has normal LDLR binding, but has altered lipid binding characteristics, with
preferential binding to triglyceride-rich VLDL and chylomicron remnants instead of phospho-
lipid-rich high-density lipoproteins[2].
The APOE ε4 allele is the minor allele in modern humans and is a major genetic risk factor
for Alzheimer’s disease[1, 2, 40]. The APOE ε4 allele also increases atherosclerosis risk and
decreases lifespan[2, 40]. APOE ε4 is the ancestral APOE allele, as it is present in all great apes,
while the shift to the APOE ε3 and APOE ε2 alleles may have reflected selective pressure from
infectious diseases[2]. Consistent with this, the human APOE ε4 allele modifies host responses
to infection, such as the human immunodeficiency virus[2, 40]. Transgenic knock-in mice
expressing the human APOE ε4 allele have increased morbidity and mortality in experimental
sepsis models[7, 41]. Similarly, human subjects heterozygous for APOE ε3/ε4 have increased
innate immune responses to LPS as compared to individuals with the APOE ε3/ε3 genotype
[41]. Furthermore, the APOE ε4 allele has been associated with increased coagulation system
failure in European Americans with severe sepsis[41]. Susceptibility to infection by the intra-
cellular bacterial pathogen, Chlamydia pneumoniae, may also be enhanced by the APOE ε4
allele by a mechanism involving increased attachment to host cells[42].
The APOE alleles, however, are not known to modulate pulmonary function in human sub-
jects and have not been linked to pulmonary function in genome-wide association studies[43–
51]. Although a prior genome-wide association study of LLFS participants identified a linkage
peak on chromosome 2 for FEV1/FVC, the APOE ε2, ε3 and ε4 alleles were not included in
that dataset[48]. Here, we show that the mean FEV1/FVC ratio was lower among women with
the ε4 allele as compared to women with either the ε3/3 genotype or the ε2 allele. In addition,
carriage of the APOE ε4 allele in the LLFS participants was associated with the FEV1/FVC
ratio, which implied a smaller value, as compared to carriers of the APOE ε3 allele. Although a
reduction in the FEV1/FVC ratio could reflect the presence of airflow obstruction, both the
FVC and FEV1 were increased in carriers of the APOE ε4 allele as compared to carriers of the
ε3/3 genotype or the ε2 allele. This suggests that the reduction in the FEV1/FVC ratio in carri-
ers of the APOE ε4 allele might instead represent modified lung physiology reflected by a pro-
portionally larger FVC than FEV1. For example, dysanaptic or unequal lung growth has been
reported to occur in teenagers, where growth of the airways, as reflected by the FEV1, relative
to lung volumes, as reflected by the FVC, occurs more slowly in girls than boys[52, 53]. Fur-
thermore, dysanaptic lung growth has been reported in the setting of chronic hypoxia and
Table 5. Associations of the APOE ε2 and ε4 alleles with FEV1, FVC, and FEV1/FVC and their multiplicative interactions with sex in the genotyped LLFS
participants.
Trait apoE apoE apoE×sex
Beta SE P-value Beta SE P-value
FEV1 ε2 -29.44 30.83 .340 13.36 43.82 .761
ε4 -33.60 29.03 .247 79.36 42.20 .060
FVC ε2 -28.98 36.97 .433 -12.70 52.56 .810
ε4 -8.92 34.56 .796 69.46 50.21 .167
FEV1/FVC ε2 -0.20 0.43 .643 0.70 0.62 .258
ε4 -1.22 0.40 .003� 1.18 0.59 .045�
The models with interactions considered men as a reference category.
The ε3/ε3 genotype was considered as the reference.
� denotes significant result (p-value < 0.05).
https://doi.org/10.1371/journal.pone.0206873.t005
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post-infectious bronchiolitis obliterans, which results in an decrease in the FEV1/FVC ratio
[53, 54]. Since the reduction in FEV1/FVC in carriers of the APOE ε4 allele was specific for
individuals over 70 years of age, we believe that it is unlikely that dysanaptic lung development
is the explanation for this finding. The FEV1/FVC ratio is well-known to decrease with advanc-
ing age, which suggests that the reduction in FEV1/FVC among carriers of the APOE ε4 allele
might instead reflect modified lung aging in older individuals[55–58]. This finding will need
to be confirmed by future studies that assess whether the reduction in FEV1/FVC among carri-
ers of the APOE ε4 allele is limited to older individuals, in which case it would not be general-
izable to younger study populations. Similarly, future studies would be required to assess
whether this finding is limited to individuals with exceptional familial longevity or is also gen-
eralizable to populations with normal longevity.
The association between the APOE ε4 allele and a lower FEV1/FVC ratio persisted when
the sub-group of LLFS women without lung disease was analyzed. To the best of our knowl-
edge, this demonstrates for the first time that an association exists between the polymorphic
APOE alleles and lung function in human subjects. Although the effect size on FEV1/FVC was
modest, the effect of an individual allele on a complex genetic trait is often relatively small. In
addition, since the effect was present in individuals without lung disease, a large magnitude of
change was not expected. Furthermore, our results suggest that a link might exist between the
APOE ε4 allele, female sex, and a lower FEV1/FVC ratio in older individuals. This may provide
a new insight regarding how the polymorphic APOE alleles might influence human lung phys-
iology in a gender-specific fashion during aging.
These data also raise the hypothesis that the APOE alleles might modify disease pathogene-
sis or severity in obstructive airway diseases, such as asthma, COPD, or asthma-COPD overlap
syndrome. In a prior study we showed that serum apoE levels were similar in normals and
asthmatics and were not correlated with FEV1, however, subjects were not stratified by APOE
genotype[59]. A limitation of this current study is that we were not able to assess if the APOE
alleles modified pulmonary function in subjects with lung disease. We did not include a sub-
group analysis of cases with lung disease for several reasons. First, lung disease was self-
reported by participants at baseline and during follow up, but the diagnosis of lung disease was
not confirmed. Second, because the types of lung disease were heterogeneous regarding diag-
noses, severity, and duration, and the number of cases with lung disease was small, an analysis
of this sub-group would likely not have sufficient power to identify an association between the
APOE alleles and pulmonary function. Third, a subset of the cases with lung disease were uti-
lizing lung disease medications, such as bronchodilators and corticosteroids, which could have
modified their pulmonary function results. Therefore, additional studies will be required to
assess whether the APOE ε4 allele is associated with modified pulmonary function in individu-
als with lung disease. Another limitation of this study is that LLFS participants were selected
based upon the trait of exceptional familial longevity. Therefore, additional studies will be
needed to assess whether the association between the FEV1/FVC ratio and the APOE ε4 allele
in older women is also present in individuals who do not have long-living families.
The mechanisms by which the APOE ε4 allele might be associated with a relative reduction in
airflow in women without lung disease are not known. Prior murine studies have identified that
the APOE/LDLR pathway is present in the lung, with the LDLR being expressed by ciliated airway
epithelial cells where it could potentially modify airway physiology[10]. Furthermore, studies
using Apoe- and Ldlr-deficient mice have shown that these genes participate in developmental
alveologenesis in a sexually dimorphic fashion[13, 14]. In addition, Apoe- and Ldlr-deficient mice
that have been sensitized and challenged with house dust mite have abnormal airway function
with increased mucous cell metaplasia and airway hyperreactivity to methacholine[10]. The
APOE ε4 allele has also been associated with enhanced risk and accelerated decline in cognitive
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function secondary to Alzheimer’s disease in women as compared to men[60]. The APOE ε4 allele
was also highly significantly associated with shorter lifespan in women as compared to men in the
LLFS study and the Framingham Heart Study[61]. Furthermore, prior studies have supported the
concept of sexual dimorphism of the ε4 allele in relationship to APOE-related mortality and heart
disease[62–65]. Gender-specific effects of the APOE gene might be attributed to differential hor-
monal and insulin regulation in each sex[62]. Collectively, these findings provide additional evi-
dence to support a gender-specific effect of the ε4 allele on the FEV1/FVC ratio.
Based upon differences in height and lung volume, absolute values for FEV1 and FVC are
known to be lower in adult women than adult men[66, 67]. Consistent with this, we found that
the absolute values for FEV1 and FVC were significantly lower in women than men, irrespec-
tive of whether they carried the APOE ε2, ε3, or ε4 allele, as evidenced by well-separated 95%
confidence intervals for FEV1 and FVC measured in men and women as +/- 1.96
�SE (Table 1).
In contrast, the FEV1/FVC ratio was not different between men and women when the sample
population was not stratified by age. Therefore, we believe that our finding of a significant
reduction in the FEV1/FVC ratio limited to the subset of older women greater or equal to 70
years of age who carried the APOE ε4 allele did not merely reflect a compounding effect of
genotype in individuals who already had lower values by virtue of sex.
In conclusion, we have identified that carriage of the APOE ε4 allele was associated with a
decrease in the FEV1/FVC ratio as compared to carriers of the APOE ε3 allele among women with-
out lung disease who participated in the LLFS. This suggests that carriage of the APOE ε4 allele
may be linked to modified lung physiology in a sexually dimorphic fashion in older individuals.
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